U.S. investment in new treatments is often driven by market potential rather than medical necessity, deepening health ...

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

Now, it’s worth noting Stock Advisor’s total average return is 1,019% — a market-crushing outperformance compared to 178 % ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

In line with the Trump administration’s goal to curb the U.S.’ reliance on overseas drug manufacturing, the FDA has deployed ...

The company reaches a $10 billion valuation and strengthens its global position in biotherapies with a strategic investment ...

Europe’s cannabis pharmaceutical sector is shifting as scientific rigour, regulatory clarity and cautious capital define its next chapter.

Consider lisinopril, approved for the treatment of hypertension in 1988, with subsequent development through the GISSI-3 trial (1994) resulting in an indication for acute myocardial infarction ...

International firms are also looking to partner with Chinese counterparts at earlier stages to co-develop drugs – such as ...